The CHA₂DS₂-VA Score: Do You Need Blood Thinners for Your AF?

The most important calculation in AF management

When a patient is first diagnosed with atrial fibrillation, one of the very first clinical questions I need to answer is: how high is their risk of a stroke — and does that risk justify blood-thinning medication? This is not a decision to take lightly. Anticoagulants reduce stroke risk substantially, but they also carry a risk of bleeding. Getting the calculation right matters enormously.

The tool we use to make this decision is a stroke risk scoring system. The most widely used in the UK and Europe is the CHA₂DS₂-VA score — updated in the 2024 European Society of Cardiology AF guidelines from the older CHA₂DS₂-VASc version that many patients and GPs may still be familiar with.

What Changed in 2024? The Move from CHA₂DS₂-VASc to CHA₂DS₂-VA

The original CHA₂DS₂-VASc score included biological sex as a risk modifier, assigning one point for being female. The 2024 ESC guidelines removed this component following analysis showing that female sex does not independently predict stroke in the way the other risk factors do — it had been inflating scores for women without meaningfully improving predictive accuracy. The updated CHA₂DS₂-VA score therefore no longer includes the sex category.

For patients previously scored using CHA₂DS₂-VASc, this means women with a score of 1 derived solely from female sex now have a CHA₂DS₂-VA score of 0 — and may not require anticoagulation. This is an important change, and worth discussing with your cardiologist if you are unsure which scoring system has been used in your assessment.

How the CHA₂DS₂-VA Score is Calculated

Each letter in the score represents a specific risk factor. Points are assigned as follows:

• C — Congestive heart failure or left ventricular dysfunction: 1 point
• H — Hypertension (high blood pressure): 1 point
• A₂ — Age 75 or older: 2 points
• D — Diabetes mellitus: 1 point
• S₂ — Stroke, TIA or previous thromboembolism: 2 points
• V — Vascular disease (prior heart attack, peripheral artery disease, or aortic plaque): 1 point
• A — Age 65–74 years: 1 point

The maximum score is 9. The higher the score, the higher the annual risk of stroke, and the greater the benefit of anticoagulation.

What Does My Score Mean?

The ESC 2024 guidelines recommend the following approach:

• Score of 0: Low risk — anticoagulation is not recommended.
• Score of 1: Intermediate risk — anticoagulation should be considered on an individual basis, taking into account bleeding risk and patient preference.
• Score of 2 or above: Elevated risk — anticoagulation is recommended.

It is important to note that a low score does not mean that AF carries no risk — it means that the risk at this time is low enough that the bleeding risk of anticoagulation is not justified. Risk scores should be reassessed regularly, particularly as patients age and accumulate additional risk factors.

Which Anticoagulant Should I Take?

The modern standard of care is a direct oral anticoagulant (DOAC) — apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), or edoxaban (Lixiana). The 2024 ESC guidelines strongly recommend DOACs over warfarin in eligible patients, because they are at least as effective at preventing AF-related stroke, have a significantly lower risk of serious bleeding — particularly intracranial bleeding — and require no routine blood monitoring.

Warfarin still has a role in specific situations, such as AF combined with mechanical heart valves or moderate-to-severe mitral stenosis, but for the vast majority of AF patients, a DOAC is now the treatment of choice.

Does Anticoagulation Mean I Do Not Need Ablation?

These are not either-or decisions. Anticoagulation reduces stroke risk, but it does not restore normal rhythm, improve symptoms, or protect the heart from the long-term damage that uncontrolled AF can cause — including AF-induced cardiomyopathy. Rhythm control through ablation addresses the AF itself. Many patients benefit from both: anticoagulation to reduce stroke risk while rhythm control is pursued through ablation.

Current guidelines recommend continuing anticoagulation for at least two months after ablation regardless of CHA₂DS₂-VA score, as the ablation healing period carries its own transient stroke risk. Long-term anticoagulation after successful ablation depends on the individual’s underlying stroke risk.

To discuss your stroke risk and treatment options, book a consultation — drboonlim.co.uk or call 0208 187 9888